Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high-risk atherothrombosis

September 2006
ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p33
Academic Journal
The article presents information on a clinical trial to assess the effectiveness of clopidogrel and aspirin for the prevention of atherothrombosis. The study was conducted by D.L. Bhatt, K.A. Fox and W. Hacke on 15,603 patients in the age group of 45-64 years of age who had multiple atherothrombotic risk factors. It was found that in patients at high risk for atherothrombosis, long-term treatment with clopidogrel plus aspirin did not differ from aspirin alone for reducing myocardial infarction.


Related Articles

  • Aspirin reverses COX-2 heart risk. Pownall, Mark // GP: General Practitioner;6/30/2006, p4 

    This article reports that according to a new research, the addition of aspirin may eliminate the cardiovascular risk of NSAID or cyclooxygenase 2 treatment. The research was presented at the European League Against Rheumatism conference in Amsterdam, the Netherlands, in June 2006. But the...

  • Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. García Rodríguez, Luis A.; González-Pérez, Antonio // BMC Medicine;2005, Vol. 3, p17 

    Background: Recent data indicate that chronic use of coxibs leads to an increased occurrence of thrombotic cardiovascular events. This raises the question as to whether traditional non-steroidal anti-inflammatory drugs (tNSAIDs) might also produce similar hazards. Our aim has been to evaluate...

  • Cyclooxygenase Inhibition and Atherothrombosis. Sohn, Hae-Young; Krötz, Florian // Current Drug Targets;Oct2006, Vol. 7 Issue 10, p1275 

    Cyclooxygenases represent a major target of pharmaceutical therapy. Cyclooxygenase inhibitors are applied in order to reduce inflammation, to relieve from pain, or to prevent atherothrombotic complications in cardiovascular disease. Inhibition of platelet aggregation by aspirin, which is due to...

  • ON SUPPORTING BELIEF.  // Bandolier;Jun2007, Vol. 14 Issue 6, p1 

    The article argues on cardiovascular problems with non-steroidal anti-inflammatory drugs and coxibs. It notes that patients taking low dose asprin (LDA) had a higher risk of myocardial infarction than those not taking LDA by a factor of at least two-fold as might be expected, so there is an...

  • Concurrent Antiplatelet and Fibrinolytic Therapy. Lange, Richard A.; Hillis, L. David // New England Journal of Medicine;3/24/2005, Vol. 352 Issue 12, p1248 

    Presents an editorial on concurrent antiplatelet and fibrinolytic therapy in patients with myocardial infarction. Combination of therapies which has been accepted in reducing mortality; How the medications work; Study in this issue on patients who were treated with fibrinolytic therapy and...

  • THE TROUBLE WITH ASPIRIN.  // Bandolier;Oct2006, Vol. 13 Issue 10, p6 

    The article evaluates the hazards of low dose aspirin (LDA). Several results of randomized trials suggest bleeding events related to LDA. However, the benefits of LDA include the prevention of heart attacks, strokes and vascular deaths. This shows that benefits outweigh the risks in taking LDA....

  • An aspirin a day reduces complications of diabetes. Guthrie, Ellen Whipple // Pharmacy Today;Oct2004, Vol. 10 Issue 10, p7 

    This article presents information on use of aspirin in diabetics. Patients with diabetes have a two- to fourfold increase in risk of dying from complications of cardiovascular disease (CVD). Aspirin decreases the risk of heart attacks and strokes. Therefore, it only makes sense that aspirin...

  • Aspirin Underutilized for Heart Health. Kiefer, Dale // Life Extension;Sep2007, Vol. 13 Issue 9, p19 

    The article discusses the results on a survey on the use of aspirin in the U.S. It was found that the percentage of Americans who regularly use the drug is disturbingly low. About 41% of them have used aspirin for preventing myocardial infarction. These findings suggest that physicians need to...

  • Review: Evidence from observational studies, but not randomized trials, suggests that long-term aspirin prevents colorectal cancer: COMMENTARY. Lebwohl, Benjamin; Neugut, Alfred I. // ACP Journal Club;Jul/Aug2007, Vol. 147 Issue 1, p15 

    The authors reflect on a study, conducted by C. Dubá and colleagues, which focuses on the effectiveness of aspirin in preventing colorectal cancer. The authors view that Dubá and colleagues highlight notable discrepancies between randomized controlled trials (RCTs) and observational...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics